EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms
- 17 March 2023
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 153 (1) , 164-172
Abstract
PNENs are relative indolent tumors with heterogeneous clinical presentation at diagnosis. It is important to establish aggressive subgroups of pNENs and identify potential therapeutic targets. Patients with pNEN (322 cases) were included to examine the association between glycosylation biomarkers and clinical/pathological traits. The molecular and metabolic features stratified by glycosylation status were assessed by RNA‐seq/whole exome sequencing and immunohistochemistry. A considerable proportion of patients had elevated glycosylation biomarkers (carbohydrate antigen [CA] 19‐9, 11.9%; CA125, 7.5%; carcinoembryonic antigen [CEA], 12.8%). CA19‐9 (hazard ratio [HR] = 2.26, P = .019), CA125 (HR = 3.79, P = .004) and CEA (HR = 3.16, P = .002) were each independent prognostic variables for overall survival. High glycosylation group, defined as pNENs with elevated level of circulating CA19‐9, CA125 or CEA, accounted for 23.4% of all pNENs. High glycosylation (HR = 3.14, P = .001) was an independent prognostic variable for overall survival and correlated with G3 grade (P < .001), poor differentiation (P = .001), perineural invasion (P = .004) and distant metastasis (P < .001). Epidermal growth factor receptor (EGFR) was enriched in high glycosylation pNENs using RNA‐seq. EGFR was expressed in 21.2% of pNENs using immunohistochemistry and associated with poor overall survival (P = .020). A clinical trial focusing on EGFR expressed pNENs was initiated (NCT05316480). Thus, pNEN with aberrant glycosylation correlates with a dismal outcome and suggests potential therapeutic target of EGFR.Keywords
Funding Information
- National Natural Science Foundation of China (U21A20374, 81871940, 82172625)
This publication has 31 references indexed in Scilit:
- CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic CancerJournal of Gastrointestinal Surgery, 2013
- Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptorBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine CarcinogenesisJournal of Clinical Oncology, 2010
- Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With CetuximabAnnals of Surgery, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomasLaboratory Investigation, 2005
- Alpha-Fetoprotein Associated with Islet Cell TumorsAmerican Journal of Clinical Oncology, 1987